Morgan Stanley
TTHI

Morgan Stanley’s TRANSITION THERAPEUTICS INC (CANADA) TTHI Stock Holding History

Morgan Stanley’s Portfolio TTHI Stock Details TTHI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,679
Closed -$7K – 6767
2016
Q2 		$7K Buy
4,679
+300
+7% +$260 ﹤0.01% 6172
2016
Q1 		$5K Buy
4,379
+237
+6% +$274 ﹤0.01% 6300
2015
Q4 		$8K Sell
4,142
-54
-1% -$103 ﹤0.01% 6306
2015
Q3 		$8K Buy
4,196
+970
+30% +$2.06K ﹤0.01% 6321
2015
Q2 		$7K Sell
3,226
-572
-15% -$4.01K ﹤0.01% 6390
2015
Q1 		$26K Sell
3,798
-2,267
-37% -$15.7K ﹤0.01% 5989
2014
Q4 		$41K Sell
6,065
-7,380
-55% -$47.7K ﹤0.01% 5873
2014
Q3 		$93K Buy
13,445
+1,973
+17% +$13.2K ﹤0.01% 5510
2014
Q2 		$77K Buy
11,472
+5,234
+84% +$30.4K ﹤0.01% 5612
2014
Q1 		$49K Sell
6,238
-7,367
-54% -$50.7K ﹤0.01% 5727
2013
Q4 		$77K Sell
13,605
-10,441
-43% -$53.5K ﹤0.01% 5449
2013
Q3 		$98K Buy
+24,046
New +$94.7K ﹤0.01% 5095

Other funds holding TTHI

HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Morgan Stanley's TTHI Position: Q3 2016 in Review

Morgan Stanley sold out of TRANSITION THERAPEUTICS INC (CANADA) (TTHI) in Q3 2016, closing a stake of 4,679 shares — an estimated $7K sold.

Morgan Stanley first reported a position in TTHI in Q3 2013 and held it in 12 quarters. The position peaked at $98K in Q3 2013. 2 funds tracked by Wall St. Rank hold TTHI as of Q3 2016.

  • Morgan Stanley reported no remaining TRANSITION THERAPEUTICS INC (CANADA) position as of Q3 2016 after selling out during the quarter.
  • Morgan Stanley sold 4,679 TRANSITION THERAPEUTICS INC (CANADA) shares in Q3 2016, an estimated $7K.
  • Morgan Stanley first reported a position in TRANSITION THERAPEUTICS INC (CANADA) in Q3 2013 and held it in 12 quarters.
  • Morgan Stanley's TRANSITION THERAPEUTICS INC (CANADA) position peaked at $98K in Q3 2013.
  • 2 funds tracked by Wall St. Rank held TRANSITION THERAPEUTICS INC (CANADA) as of Q3 2016.

Based on Morgan Stanley's 13F filing for Q3 2016, filed 10 Nov 2016.